Right heart dysfunction and failure in heart failure with preserved ejection fraction

Thomas M Gorter, Dirk J van Veldhuisen, Johann Bauersachs, Barry A Borlaug, Jelena Celutkiene, Andrew J S Coats, Marisa G Crespo-Leiro, Marco Guazzi, Veli-Pekka Harjola, Stephane Heymans, Loreena Hill, Mitja Lainscak, Carolyn S P Lam, Lars H Lund, Alexander R Lyon, Alexandre Mebazaa, Christian Mueller, Walter J Paulus, Burkert Pieske, Massimo F PiepoliFrank Ruschitzka, Frans H Rutten, Petar M Seferovic, Scott D Solomon, Sanjiv J Shah, Filippos Triposkiadis, Rolf Wachter, Carsten Tschöpe, Rudolf A de Boer

Research output: Contribution to journalReview articlepeer-review

170 Citations (Scopus)
1 Downloads (Pure)

Abstract

There is an unmet need for effective treatment strategies to reduce morbidity and mortality in patients with heart failure with preserved ejection fraction (HFpEF). Until recently, attention in patients with HFpEF was almost exclusively focused on the left side. However, it is now increasingly recognized that right heart dysfunction is common and contributes importantly to poor prognosis in HFpEF. More insights into the development of right heart dysfunction in HFpEF may aid to our knowledge about this complex disease and may eventually lead to better treatments to improve outcomes in these patients. In this position paper from the Heart Failure Association of the European Society of Cardiology, the Committee on Heart Failure with Preserved Ejection Fraction reviews the prevalence, diagnosis, and pathophysiology of right heart dysfunction and failure in patients with HFpEF. Finally, potential treatment strategies, important knowledge gaps and future directions regarding the right side in HFpEF are discussed.

Original languageEnglish
Number of pages22
JournalEuropean Journal of Heart Failure
Volume20
Issue number1
Early online date16-Oct-2017
DOIs
Publication statusPublished - Jan-2018

Keywords

  • Journal Article
  • Review
  • DIASTOLIC DYSFUNCTION
  • INVASIVE HEMODYNAMICS
  • RIGHT-VENTRICULAR FUNCTION
  • PULMONARY ARTERIAL-HYPERTENSION
  • RANDOMIZED CONTROLLED-TRIAL
  • CARDIAC MAGNETIC-RESONANCE
  • CHRONIC KIDNEY-DISEASE
  • EXERCISE CAPACITY
  • ATRIAL-FIBRILLATION
  • PHOSPHODIESTERASE-5 INHIBITION

Cite this